Advertisement
INOVIO Reports Positive Interim Phase 1/2 Trial Results For INO-3107 For Respiratory Papillomatosis
(RTTNews) - Biotechnology company Inovio Pharmaceuticals Inc. (INO) announced Thursday positive interim results from an ongoing Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults.
In the first cohort of 21 participants, INO-3107 showed a statistically significant improvement in the clinical endpoint of the number of surgical interventions needed to control papilloma growth.
INO-3107 was also observed to be well-tolerated and immunogenic in the trial. INO-3107 received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in July 2020.
INO-3107 was evaluated in a Phase 1/2 open-label, multicenter trial to assess its safety, tolerability, immunogenicity, and efficacy in 32 participants with HPV 6 and/or HPV 11-associated RRP.
Results from the second cohort of 11 patients are expected in the first half of 2023.
For More Such Health News, visit rttnews.com
Inovio Pharma Receives FDA Feedback On Submission Of BLA For INO-3107 To Treat RRP
INOVIO Says FDA Grants Breakthrough Therapy Designation For INO-3107; Stock Up 15%
INOVIO Pharma Announces Positive Results From Phase 1b Clinical Trial Evaluating INO-4201
INOVIO Announces Corporate Reorganization, Including Workforce Reduction, To Reduce Expenses
Australia June Trade Surplus A$5.365 Billion
Australia Building Approvals Jump 11.9% In June
Japanese Market Notably Higher
